GLP-1s vs. the Diabetes Prevention Program for Prediabetes Compared
For most people with prediabetes, a structured lifestyle program like the Diabetes Prevention Program (DPP) is the proven, low-cost first step. It cut diabetes risk by 58% in its landmark trial, and the effect was still measurable 15 years later. GLP-1 medications can cut risk even further, by 94% with tirzepatide in a 3-year trial, but they cost far more, are not approved for prediabetes on its own, and the benefit fades after stopping.
Key takeaways
- In the original DPP trial, intensive lifestyle change lowered type 2 diabetes risk by 58% versus placebo (71% in people 60 and older); metformin lowered it by 31%.
- In people with obesity and prediabetes, tirzepatide reduced progression to type 2 diabetes by 94% versus placebo over about 3.4 years, with 15% to 23% weight loss.
- Medicare covers the Medicare Diabetes Prevention Program at no cost to eligible beneficiaries. Self-pay GLP-1s run about $149 to $449 a month as of October 2026.
- Since July 2026, Medicare beneficiaries with a BMI of 27 or higher plus prediabetes may qualify for $50-a-month GLP-1s through the Medicare GLP-1 Bridge.
Why this decision matters
The CDC says more than 2 in 5 American adults have prediabetes, and that losing about 5% to 7% of body weight can lower the risk of type 2 diabetes. Both options here aim at that goal by very different routes. One changes habits with coaching. The other changes appetite with a drug.
Side-by-side comparison
| Factor | Diabetes Prevention Program (lifestyle) | GLP-1 medication |
|---|---|---|
| What it is | Yearlong coach-led program, in person or online | Weekly injection or daily pill, taken ongoing |
| Diabetes risk reduction in landmark trial | 58% vs. placebo over about 3 years | 94% vs. placebo over 176 weeks (tirzepatide, people with obesity and prediabetes) |
| Average weight loss | 5.6 kg (trial); program goal 5% to 7% | 15.4% to 22.9% at 176 weeks, depending on dose |
| Long-term effect | Diabetes still 27% lower at 15 years | Weight returns and risk rises after stopping |
| FDA status for prediabetes | Not a drug; CDC-recognized programs | Not approved for prediabetes alone; approved for obesity or overweight with a related condition |
| Basic eligibility | 18+, BMI 25+ (23+ if Asian American), prediabetes lab result, prior gestational diabetes, or high risk-test score | Prescriber decision based on label criteria |
| Cost | $0 for eligible Medicare beneficiaries; other plans and employers may cover | About $149 to $449/month self-pay; $50/month via Medicare Bridge if eligible |
| Side effects | None from a drug | Nausea, vomiting, diarrhea; pancreatitis, gallbladder warnings |
Source: NIDDK, ACC DPP summary, Eli Lilly (SURMOUNT-1, 3-year), CDC eligibility, Medicare.gov, manufacturer pricing. These trials enrolled different people and used different methods, so the risk reductions are not a direct head-to-head.
What the Diabetes Prevention Program showed
The DPP trial enrolled 3,234 adults with prediabetes and an average BMI of 34. The lifestyle group aimed to lose 7% of body weight and get 150 minutes of activity a week. Over an average of 2.8 years, they lost 5.6 kg on average, compared with 2.1 kg on metformin and 0.1 kg on placebo (ACC).
The results on diabetes were striking. According to the NIDDK, lifestyle change lowered risk by 58% versus placebo, and by 71% in people 60 and older. Metformin lowered it by 31%.
The long-term follow-up is where lifestyle change shines. At 10 years, the lifestyle group had delayed diabetes by 34%, and at 15 years by 27%. Even so, about 55% of the lifestyle group had developed diabetes by 15 years, compared with 62% on placebo, so the program delays diabetes more often than it prevents it outright.
What GLP-1s showed in prediabetes
About 40.6% of people in SURMOUNT-1, a tirzepatide trial in adults with obesity, had prediabetes at the start (ACC). Those participants were followed for 176 weeks. Tirzepatide reduced the risk of developing type 2 diabetes by 94% versus placebo, with average weight loss of 15.4% to 22.9% depending on dose, compared with 2.1% on placebo (Eli Lilly).
The catch came after the drug stopped. During a 17-week off-treatment period, participants regained weight and their diabetes risk rose somewhat, though it was still 88% lower than placebo at that point. A separate trial, SURMOUNT-4, showed how quickly weight returns: people switched from tirzepatide to placebo regained 14% of body weight within a year (JAMA, 2024).
Considering medication for prediabetes?
Compare current GLP-1 options and what they cost before your next appointment.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Cost and access
The lifestyle program
The CDC-recognized National DPP lifestyle change program runs for a year, is led by a trained lifestyle coach, and is offered both in person and online (CDC). To join, the CDC says you must be 18 or older, have a BMI of 25 or more (23 or more if Asian American), have no prior diabetes diagnosis, not be pregnant, and have a prediabetes test result, a history of gestational diabetes, or a high score on the CDC risk test (CDC).
For Medicare beneficiaries, the Medicare Diabetes Prevention Program is covered under Part B at no cost if you qualify. It includes 16 weekly core sessions over six months, then six monthly maintenance sessions (Medicare.gov). CMS now allows fully online, self-paced delivery through December 31, 2029 (CMS). Outside Medicare, cost depends on your plan or employer, which may cover a program.
GLP-1s
Self-pay prices as of October 2026: Wegovy injections are $349 a month, with the Wegovy pill launched at $149 to $299 depending on dose (Fierce Pharma). Zepbound runs $299 to $449 with Lilly's self-pay card (Lilly).
Medicare changed the math in 2026. The Medicare GLP-1 Bridge, which started July 1, 2026, offers Wegovy, Foundayo, or the Zepbound KwikPen for $50 a month. People with a BMI of 27 or higher plus prediabetes are among those who can qualify, if they have Part D coverage and meet the program's other requirements.
Side effects and effort
The DPP asks for time and sustained effort: weekly sessions, food tracking, and regular activity. There is no drug side-effect risk. GLP-1s ask less behavior change up front but bring side effects. On the Wegovy label, nausea affected 44% of users versus 16% on placebo, and diarrhea 30%. Warnings include pancreatitis and gallbladder disease.
What about metformin?
Metformin is the third option the original DPP tested. It reduced risk by 31%, and the NIDDK notes it worked best in people aged 25 to 44, those with a BMI of 35 or higher, and women with a history of gestational diabetes. It is inexpensive, but its effect was smaller than lifestyle change in the trial.
Which path fits you
Start with a DPP program if
- Your BMI is in the overweight or lower obesity range and a 5% to 7% loss is realistic.
- You want a durable result without ongoing drug costs.
- You have Medicare or employer coverage that makes the program free or cheap.
- You are 60 or older, the group where the lifestyle program performed best.
Ask about a GLP-1 if
- You meet the label criteria for obesity, or overweight with another weight-related condition.
- You completed a lifestyle program and your glucose numbers are still climbing.
- You need substantial weight loss for other health reasons, such as sleep apnea or heart risk.
- You qualify for coverage or the Medicare Bridge and expect to stay on the medication long term.
These paths are not mutually exclusive. GLP-1 labels already call for use alongside a reduced-calorie diet and more physical activity, the same habits a DPP program teaches.
The verdict
For most people with prediabetes, the Diabetes Prevention Program should come first. It cut diabetes risk by 58% in its trial, keeps working for years after the program ends, carries no drug risks, and is free for eligible Medicare beneficiaries. GLP-1s produce more weight loss and a larger short-term risk reduction (94% with tirzepatide), so they are a strong option if you also have obesity, a lifestyle program has not been enough, or coverage makes them affordable. Because the benefit fades when the drug stops, treat a GLP-1 as a long-term commitment and decide with your clinician.
Check GLP-1 pricing
See what providers currently charge if medication is part of your plan.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Frequently asked questions
Is a GLP-1 better than the Diabetes Prevention Program for prediabetes?
GLP-1s produce more weight loss and a larger short-term risk reduction; tirzepatide cut progression to diabetes by 94% versus placebo over 176 weeks. The DPP lifestyle program cut risk by 58% in its trial, costs far less, and its effect was still measurable 15 years later, so it remains the usual first step.
Are GLP-1 drugs approved for prediabetes?
No GLP-1 is FDA-approved for prediabetes by itself. Wegovy and Zepbound are approved for adults with obesity, or overweight plus a weight-related condition, which includes many people with prediabetes.
Does Medicare cover the Diabetes Prevention Program?
Yes. The Medicare Diabetes Prevention Program is covered under Part B at no cost for eligible beneficiaries and includes 16 weekly core sessions followed by six monthly maintenance sessions.
Can Medicare patients with prediabetes get a GLP-1?
Possibly. Since July 1, 2026, the Medicare GLP-1 Bridge offers certain GLP-1s for $50 a month, and a BMI of 27 or higher plus prediabetes is one of the qualifying criteria, along with Part D coverage and other requirements.
What happens to diabetes risk if you stop a GLP-1?
In the tirzepatide prediabetes study, people regained weight and their diabetes risk rose somewhat during a 17-week off-treatment period, though it was still 88% lower than placebo at that point.
Sources
- Diabetes Prevention Program (DPP), NIDDK
- Diabetes Prevention Program trial summary, American College of Cardiology
- Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity, Eli Lilly (2024)
- SURMOUNT-1 trial summary, American College of Cardiology
- Continued tirzepatide for maintenance of weight reduction (SURMOUNT-4), JAMA (2024)
- Prediabetes: your chance to prevent type 2 diabetes, CDC
- National DPP lifestyle change program, CDC
- Are you eligible for the lifestyle change program? CDC
- Medicare Diabetes Prevention Program coverage, Medicare.gov
- Medicare Diabetes Prevention Program expanded model, CMS
- Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month, Medicare.gov
- Wegovy prescribing information, FDA (2025)
- Zepbound prescribing information, Eli Lilly
- Wegovy pill launches at $149 per month, Fierce Pharma
- Zepbound coverage and savings, Eli Lilly
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.